{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:24:02Z","timestamp":1789982642371,"version":"4.0.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:00:00Z","timestamp":1516320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1038\/nrneurol.2017.186","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:21:59Z","timestamp":1516321319000},"page":"65-66","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Progress towards therapy in motor neuron disease"],"prefix":"10.1038","volume":"14","author":[{"given":"Matthew C.","family":"Kiernan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,19]]},"reference":[{"key":"BFnrneurol2017186_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1136\/jnnp-2017-315573","volume":"88","author":"A Eisen","year":"2017","unstructured":"Eisen, A.  et al. Cortical influences drive amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 88, 917\u2013924 (2017).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2017186_CR2","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S.  et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2017186_CR3","doi-asserted-by":"crossref","unstructured":"The Writing Group. Safety and efficacy of edaravone inwell defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16, 505\u2013512 (2017).","DOI":"10.1016\/S1474-4422(17)30115-1"},{"key":"BFnrneurol2017186_CR4","doi-asserted-by":"crossref","unstructured":"Mora, J. S., Barbeito, L. & Hermine, O. Masitinib as an add-on therapy to riluzole is beneficial in the treatment of amyotrophic lateral sclerosis (ALS) with acceptable tolerability: results from a randomized controlled phase 3 trial. European Network to Cure ALS (ENCALS) \n                    http:\/\/videolectures.net\/encals2017_barbeito_mora_hermine_therapy\/\n                    \n                   (2017).","DOI":"10.1016\/j.jns.2017.08.526"},{"key":"BFnrneurol2017186_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S1474-4422(16)30399-4","volume":"16","author":"V Meininger","year":"2017","unstructured":"Meininger, V.  et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 16, 208\u2013216 (2017).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2017186_CR6","doi-asserted-by":"publisher","unstructured":"van Eijk, R. P. A.  et al. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry \n                    https:\/\/doi.org\/10.1136\/jnnp-2017-317077\n                    \n                   (2017).","DOI":"10.1136\/jnnp-2017-317077"},{"key":"BFnrneurol2017186_CR7","doi-asserted-by":"publisher","first-page":"14774","DOI":"10.1038\/ncomms14774","volume":"8","author":"RL McLaughlin","year":"2017","unstructured":"McLaughlin, R. L.  et al. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nat. Commun. 8, 14774 (2017).","journal-title":"Nat. Commun."},{"key":"BFnrneurol2017186_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","volume":"377","author":"MC Kiernan","year":"2011","unstructured":"Kiernan, M. C.  et al. Amyotrophic lateral sclerosis. Lancet 377, 942\u2013955 (2011).","journal-title":"Lancet"},{"key":"BFnrneurol2017186_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jnnp-2014-309829","volume":"86","author":"MR Turner","year":"2015","unstructured":"Turner, M. R. & Kiernan, M. C. The standard of care in amyotrophic lateral sclerosis: a centralised multidisciplinary clinic encounter sets a new benchmark for a uniquely challenging neurodegenerative disorder. J. Neurol. Neurosurg. Psychiatry 86, 481\u2013482 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2017186_CR10","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1212\/WNL.0000000000004606","volume":"89","author":"RPA van Eijk","year":"2017","unstructured":"van Eijk, R. P. A.,  et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 89, 1915\u20131922 (2017).","journal-title":"Neurology"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2017.186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2017.186","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrneurol.2017.186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2017.186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:21:44Z","timestamp":1684455704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2017.186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,19]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["BFnrneurol2017186"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2017.186","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,19]]},"assertion":[{"value":"19 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}